Serum samples were collected from patients with PsA to create a biomarker discovery cohort and a validation cohort. Patients with PsA were classified into axial or peripheral subtypes based on imaging criteria. Liquid chromatography-mass spectrometry was used in the discovery phase to screen for biomarkers, and candidate biomarkers were validated using enzyme-linked immunosorbent assay (ELISA) in the validation cohort.